Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer.
Humans
Deoxycytidine
/ therapeutic use
Pandemics
Retrospective Studies
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
COVID-19
/ epidemiology
Pancreatic Neoplasms
/ therapy
Albumins
/ therapeutic use
Paclitaxel
/ therapeutic use
Terminal Care
Fluorouracil
/ therapeutic use
Pancreatic Neoplasms
COVID-19
chemotherapy
end-of-life care
pancreatic cancer
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
15 Dec 2022
15 Dec 2022
Historique:
pubmed:
6
10
2022
medline:
17
12
2022
entrez:
5
10
2022
Statut:
ppublish
Résumé
Objective The coronavirus disease (COVID-19) pandemic has altered the delivery of medical care. The present study evaluated the impact of COVID-19 on the outcomes of unresectable pancreatic cancer (PC) patients who received end-of-life care. Methods We retrospectively compared the management of PC patients during the COVID-19 pandemic (from April 2020 to March 2021) to the preceding year, which was unaffected by the pandemic (from April 2019 to March 2020), based on a prospectively maintained institutional database. Results A total of 178 patients were included in the COVID-19-exposed group and 201 patients were included in the COVID-19-unexposed group. The median overall survival was similar between the groups (exposed vs. unexposed: 12.6 vs. 11.9 months, p=0.174). Treatment regimens and relative dose intensities and the progression-free survival of GnP (gemcitabine in combination with nab-paclitaxel) and mFOLFIRINOX as first- and second-line chemotherapy did not differ significantly between the two groups. Only 9.0% of patients died at home in the COVID-19-unexposed group, compared to 32.0% in the COVID-19-exposed group (p<0.001). A multivariate analysis revealed that death during the COVID-19 exposed period was independently associated with home death (odds ratio: 4.536, 95% confidence interval: 2.527-8.140, p<0.001). Conclusions While the COVID-19 pandemic did not seem to influence chemotherapeutic treatment for PC patients at our institution, it had a large impact on end-of-life care. These findings may promote discussion about end-of-life care in Japan.
Identifiants
pubmed: 36198597
doi: 10.2169/internalmedicine.0492-22
pmc: PMC9841099
doi:
Substances chimiques
Deoxycytidine
0W860991D6
Albumins
0
Paclitaxel
P88XT4IS4D
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3641-3649Références
Cancer Chemother Pharmacol. 2016 Mar;77(3):595-603
pubmed: 26842789
JAMA. 2020 May 26;323(20):2005-2006
pubmed: 32282023
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
J Epidemiol. 2021 Jul 03;:
pubmed: 34219122
N Engl J Med. 2020 Jun 11;382(24):2285-2287
pubmed: 32267650
Invest New Drugs. 2018 Oct;36(5):939-948
pubmed: 29572783
Int J Clin Oncol. 2021 Feb;26(2):335-344
pubmed: 33085057
PLoS Med. 2013;10(3):e1001410
pubmed: 23555201
ESMO Open. 2020 Apr;5(2):
pubmed: 32354722
Cancer Chemother Pharmacol. 2017 Mar;79(3):595-602
pubmed: 28236000
Cancer Sci. 2014 Oct;105(10):1321-6
pubmed: 25117729
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Lancet Oncol. 2020 May;21(5):619-621
pubmed: 32220659
Lancet. 2016 Feb 6;387(10018):545-557
pubmed: 26615328
Cancer Chemother Pharmacol. 2018 Jun;81(6):1017-1023
pubmed: 29633005
JCO Oncol Pract. 2020 Jul;16(7):383-388
pubmed: 32352884
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
BMC Cancer. 2020 May 20;20(1):449
pubmed: 32434547
Arch Gerontol Geriatr. 2018 Sep - Oct;78:196-202
pubmed: 30006212
BMC Palliat Care. 2019 Jan 28;18(1):13
pubmed: 30691417
Jpn J Clin Oncol. 2017 Sep 01;47(9):832-839
pubmed: 28541474
Jpn J Clin Oncol. 2021 Aug 30;51(9):1416-1422
pubmed: 34128055
Support Care Cancer. 2012 Oct;20(10):2575-82
pubmed: 22270089
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140